数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Novel tools for absolute quantification of established and emerging fluid neuro-biomarkers are required to advance diagnostic studies and improve biological insights.
方法
We conducted an extensive analytical and clinical validation of the Olink™ Target 48 Neurodegeneration panel (T48 Neuropanel) in 352 paired cerebrospinal fluid (CSF) and plasma samples from cognitively unimpaired controls (CU), Alzheimer's dementia (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), n = 44 per group.
核心结论
Comparisons with benchmark assays were performed.；Good detectability (CSF: 31 out of 42 assays; plasma: 38 out of 42 assays) and technical performance was observed.；Benchmark assays showed good correlations, supporting transformation formula's.；Next to emerging biomarkers (MMP10, ITGB2), discriminative performance was excellent in AD: CSF pTau217: area under the curve (AUC) = 1; FTD: plasma neurofilament light chain (NfL): AUC = 0.952; and DLB: CSF dopa decarboxylase (DDC): AUC = 0.901. ‖ 结论：Next to emerging biomarkers (MMP10, ITGB2), discriminative performance was excellent in AD: CSF pTau217: area under the curve (AUC) = 1； FTD: plasma neurofilament light chain (NfL): AUC = 0.952； and DLB: CSF dopa decarboxylase (DDC): AUC = 0.901.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★★☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。顶刊证据。
原文题录
- 英文标题：The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders.
- 期刊与标识：Alzheimers Dement · PMID 42949229 · DOI 10.1002/alz.71866**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。